Prime

Type your tag names separated by a space and hit enter

[Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients].

Abstract

The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated. Method: open, non-controlled surveillance study conducted at 744 centers.

Patients:

3,076 patients suffering from bronchitis. Medication: 600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose. End points: evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance.

Results:

impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%).

Conclusions:

treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated.

Authors

,

Source

Fortschritte der Medizin 109:34 1991 Nov 30 pg 707-10

MeSH

Acetylcysteine
Administration, Oral
Bronchitis
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Pilot Projects

Pub Type(s)

English Abstract
Journal Article

Language

ger

PubMed ID

1765342

Citation

TY - JOUR T1 - [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. AU - Gerards,H H, AU - Vits,U, PY - 1991/11/30/pubmed PY - 1991/11/30/medline PY - 1991/11/30/entrez SP - 707 EP - 10 JF - Fortschritte der Medizin JO - Fortschr. Med. VL - 109 IS - 34 N2 - The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated. Method: open, non-controlled surveillance study conducted at 744 centers. Patients: 3,076 patients suffering from bronchitis. Medication: 600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose. End points: evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance. Results: impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%). Conclusions: treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated. SN - 0015-8178 UR - https://www.unboundmedicine.com/medline/citation/1765342/ L2 - http://www.labome.org//expert/germany/wilke/robert-wilke-1765342.html ER -